Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 9781715, 9 pages
http://dx.doi.org/10.1155/2016/9781715
Research Article

Danshen (Salvia miltiorrhiza) Compounds Improve the Biochemical Indices of the Patients with Coronary Heart Disease

1Department of Geriatrics, Affiliated Hospital, Changchun University of Traditional Chinese Medicine, Changchun 130000, China
2Department of Neurology, Jilin Province People’s Hospital, Changchun 130000, China

Received 25 February 2016; Revised 16 April 2016; Accepted 3 May 2016

Academic Editor: Roja Rahimi

Copyright © 2016 Boyan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Leigh, M. Alvarez, and C. J. Rodriguez, “Ethnic minorities and coronary heart disease: an update and future directions,” Current Atherosclerosis Reports, vol. 18, no. 2, article 9, 2016. View at Publisher · View at Google Scholar
  2. J. S. Kanu, Y. Gu, S. Zhi et al., “Single nucleotide polymorphism rs3774261 in the AdipoQ gene is associated with the risk of coronary heart disease (CHD) in Northeast Han Chinese population: a case-control study,” Lipids in Health and Disease, vol. 15, no. 1, p. 6, 2016. View at Publisher · View at Google Scholar
  3. L. Anderson, D. R. Thompson, N. Oldridge et al., “Exercise-based cardiac rehabilitation for coronary heart disease,” Journal of the American College of Cardiology, vol. 67, no. 1, pp. 1–12, 2016. View at Publisher · View at Google Scholar
  4. X.-Y. Zhang, L. Shu, C.-J. Si et al., “Dietary patterns, alcohol consumption and risk of coronary heart disease in adults: a meta-analysis,” Nutrients, vol. 7, no. 8, pp. 6582–6605, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Zhao, H. Zhao, L. Wang, S. Du, and Y. Qin, “Education is critical for medication adherence in patients with coronary heart disease,” Acta Cardiologica, vol. 70, no. 2, pp. 197–204, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. S. K. Agarwal, A. Kapoor, S. Pande et al., “Comparison of release kinetics of different cardiac biomarkers in patients undergoing off pump coronary artery bypass surgery and valve replacement surgery for rheumatic heart disease,” Journal of Cardiothoracic Surgery, vol. 10, supplement 1, article A208, 2015. View at Publisher · View at Google Scholar
  7. H. Cao, J. Zhai, W. Mu et al., “Use of comparative effectiveness research for similar Chinese patent medicine for angina pectoris of coronary heart disease: a new approach based on patient-important outcomes,” Trials, vol. 15, article 84, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Luo, W. Song, G. Yang, H. Xu, and K. Chen, “Compound Danshen (Salvia miltiorrhiza) dripping pill for coronary heart disease: an overview of systematic reviews,” The American Journal of Chinese Medicine, vol. 43, no. 1, pp. 25–43, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. T. O. Cheng, “Danshen: a versatile Chinese herbal drug for the treatment of coronary heart disease,” International Journal of Cardiology, vol. 113, no. 3, pp. 437–438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. G.-J. Zhou, W. Wang, X.-M. Xie, M.-J. Qin, B.-K. Kuai, and T.-S. Zhou, “Post-harvest induced production of salvianolic acids and significant promotion of antioxidant properties in roots of Salvia miltiorrhiza (Danshen),” Molecules, vol. 19, no. 6, pp. 7207–7222, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J.-Y. Han, J.-Y. Fan, Y. Horie et al., “Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion,” Pharmacology and Therapeutics, vol. 117, no. 2, pp. 280–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Stumpf, Q. Fan, C. Hintermann et al., “Anti-inflammatory effects of Danshen on human vascular endothelial cells in culture,” The American Journal of Chinese Medicine, vol. 41, no. 5, pp. 1065–1077, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Wang, R. Zhao, B. Li, L. Y. Gu, and H. Gou, “An in vivo and in vitro study: high-dosage Danshen injection induces peripheral vascular endothelial cells injury,” Human & Experimental Toxicology, vol. 35, no. 4, pp. 404–417, 2016. View at Publisher · View at Google Scholar
  14. Y. Chen, N. Zhang, J. Ma et al., “A Platelet/CMC coupled with offline UPLC-QTOF-MS/MS for screening antiplatelet activity components from aqueous extract of Danshen,” Journal of Pharmaceutical and Biomedical Analysis, vol. 117, pp. 178–183, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. C. M. Gamboa, M. M. Safford, E. B. Levitan et al., “Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease,” American Journal of the Medical Sciences, vol. 348, no. 2, pp. 108–114, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Huang, H. D. Ye, X. Gao et al., “Significant interaction of APOE rs4420638 polymorphism with HDL-C and APOA-I levels in coronary heart disease in Han Chinese men,” Genetics and Molecular Research, vol. 14, no. 4, pp. 13414–13424, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Gong, S. Li, L. Hu et al., “Total cholesterol mediates the effect of ABO blood group on coronary heart disease,” Zhonghua Xin Xue Guan Bing Za Zhi, vol. 43, no. 5, pp. 404–407, 2015. View at Google Scholar
  18. A. Onat, “Influence of gender, C- reactive protein and triglycerides in risk prediction of coronary heart disease,” Anadolu Kardiyoloji Dergisi, vol. 13, no. 3, pp. 287–288, 2013. View at Publisher · View at Google Scholar
  19. L. Zhu, Z. Lu, and Y. Y. Song, “Advances in the association between apolipoprotein (a) gene polymorphisms and coronary heart disease,” Zhongguo Yi Xue Ke Xue Yuan Xue Bao, vol. 37, no. 4, pp. 482–488, 2015. View at Google Scholar
  20. J. Z. Zhang, Y. Y. Zheng, Y. N. Yang et al., “Association between apolipoprotein B gene polymorphisms and the risk of coronary heart disease (CHD): an update meta-analysis,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 16, no. 4, pp. 827–837, 2015. View at Publisher · View at Google Scholar
  21. G. D. Kolovou, V. Kolovou, D. B. Panagiotakos et al., “Study of common variants of the apolipoprotein E and lipoprotein lipase genes in patients with coronary heart disease and variable body mass index,” Hormones, vol. 14, no. 3, pp. 376–382, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. E. V. Mazdorova, K. Y. Nikolaev, Y. V. Polonskaya et al., “Valuing the lipid marker of lipoprotein (a) in the diagnosis of patients with coronary heart disease,” Kardiologiia, vol. 55, no. 8, p. 49, 2015. View at Google Scholar · View at Scopus
  23. Y. Hashimoto, A. Futamura, H. Nakarai, and K. Nakahara, “Relationship between response of γ-glutamyl transpeptidase to alcohol drinking and risk factors for coronary heart disease,” Atherosclerosis, vol. 158, no. 2, pp. 465–470, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Oda and R. Kawai, “A possible cross-sectional association of serum total bilirubin with coronary heart disease and stroke in a Japanese health screening population,” Heart and Vessels, vol. 27, no. 1, pp. 29–36, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Ghem, R. E. Sarmento-Leite, A. S. de Quadros, S. Rossetto, and C. A. M. Gottschall, “Serum bilirubin concentration in patients with an established coronary artery disease,” International Heart Journal, vol. 51, no. 2, pp. 86–91, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Lin, H. Zhang, F. Huang, H. Chen, C. Lin, and P. Zhu, “Influence of changes in serum uric acid levels on renal function in elderly patients with hypertension: a retrospective cohort study with 3.5-year follow-up,” BMC Geriatrics, vol. 16, no. 1, article 35, 2016. View at Publisher · View at Google Scholar
  27. D. R. Kannangara, G. G. Graham, K. M. Williams, and R. O. Day, “Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine,” Clinical Rheumatology, 2016. View at Publisher · View at Google Scholar
  28. B. Ekici, U. Kütük, A. Alhan, and H. F. Töre, “The relationship between serum uric acid levels and angiographic severity of coronary heart disease,” Kardiologia Polska, vol. 73, no. 7, pp. 533–538, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Han, Q. Wu, C. Wang et al., “Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: a population-based, prospective cohort study,” Stroke, vol. 46, no. 7, pp. 1777–1786, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Sertoglu, H. Kayadibi, and M. Uyanik, “Biochemical view on ‘Homocysteine and metabolic syndrome: from clustering to additional utility in prediction of coronary heart disease’,” Journal of Cardiology, vol. 65, no. 5, p. 439, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. Li, L. Zhu, and B. Huang, “Effects of purified herbal extract of Salvia miltiorrhiza on lipid profile in hyperlipidemic patients,” Journal of Geriatric Cardiology, vol. 6, no. 2, pp. 99–101, 2009. View at Google Scholar · View at Scopus
  32. C. Zhu, H. Cao, X. Zhou et al., “Meta-analysis of the clinical value of danshen injection and huangqi injection in liver cirrhosis,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 842824, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Lu, Y. Jin, L. Ma, and L. Du, “Danshen (Radix Salviae Miltiorrhizae) reverses renal injury induced by myocardial infarction,” Journal of Traditional Chinese Medicine, vol. 35, no. 3, pp. 306–311, 2015. View at Google Scholar · View at Scopus
  34. General Assembly of the World Medical Association, “World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects,” The Journal of the American College of Dentists, vol. 81, no. 3, pp. 14–18, 2014. View at Google Scholar
  35. American College of Cardiology and American Heart Association Task Force on Practice, “ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations,” Catheterization and Cardiovascular Interventions, vol. 51, no. 4, pp. 505–521, 2000. View at Google Scholar
  36. S. Senol, M. U. Es, G. Gokmen, O. Ercin, B. A. Tuylu, and K. Kargun, “Genetic polymorphisms in preoperative myocardial infarction,” Asian Cardiovascular and Thoracic Annals, vol. 23, no. 4, pp. 389–393, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. T. N. Sheth, O. A. Kajander, S. Lavi et al., “Optical coherence tomography-guided percutaneous coronary intervention in ST-segment-elevation myocardial infarction: a prospective propensity-matched cohort of the thrombectomy versus percutaneous coronary intervention alone trial,” Circulation: Cardiovascular Interventions, vol. 9, no. 4, Article ID e003414, 2016. View at Publisher · View at Google Scholar
  38. M. A. Becker, H. R. Schumacher Jr., R. L. Wortmann et al., “Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout,” Arthritis & Rheumatism, vol. 52, no. 3, pp. 916–923, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. S. H. Park, M. H. Jeong, I. H. Park et al., “Effects of combination therapy of statin and N-acetylcysteine for the prevention of contrast–induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention,” International Journal of Cardiology, vol. 212, pp. 100–106, 2016. View at Publisher · View at Google Scholar
  40. A. Auricchio, C. Stellbrink, S. Sack et al., “Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay,” Journal of the American College of Cardiology, vol. 39, no. 12, pp. 2026–2033, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Qiu, J. Jiang, Y. Ma et al., “Opposite effects of single-dose and multidose administration of the ethanol extract of danshen on CYP3A in healthy volunteers,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 730734, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Gong, Y. Li, and H. Qu, “Removing tannins from medicinal plant extracts using an alkaline ethanol precipitation process: a case study of Danshen injection,” Molecules, vol. 19, no. 11, pp. 18705–18720, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Jia, F. Huang, S. Zhang, and S.-W. Leung, “Is danshen (Salvia miltiorrhiza) dripping pill more effective than isosorbide dinitrate in treating angina pectoris? A systematic review of randomized controlled trials,” International Journal of Cardiology, vol. 157, no. 3, pp. 330–340, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. C. L. Ogden and M. D. Carroll, Prevalence of Overweight, Obesity, and Extreme Obesity among Adults: United States, Trends 1960–1962 through 2007-2008, vol. 6, National Center for Health Statistics, Hyattsville, Md, USA, 2010.
  45. T. O. Cheng, “Cardiovascular effects of Danshen,” International Journal of Cardiology, vol. 121, no. 1, pp. 9–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. G.-I. Zhang, X.-D. Wei, B.-J. Fang et al., “The study of preventing hepatic veno-occlusive disease with danshen for injection,” Proceeding of Clinical Medicine, vol. 8, article 30, 2010. View at Google Scholar
  47. H. Wu and X. Zhang, “The study on the effect of compound danshen dripping pills on the activity of CYP1A2, NAT2, and XO,” Chinese Journal of Modern Applied Pharmacy, vol. 1, article 5, 2009. View at Google Scholar
  48. A. H. Hainsworth, N. E. Yeo, E. M. Weekman, and D. M. Wilcock, “Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID),” Biochimica et Biophysica Acta, vol. 1862, no. 5, pp. 1008–1017, 2016. View at Publisher · View at Google Scholar
  49. E. Bukharaeva, A. Shakirzyanova, V. Khuzakhmetova, G. Sitdikova, and R. Giniatullin, “Homocysteine aggravates ROS-induced depression of transmitter release from motor nerve terminals: potential mechanism of peripheral impairment in motor neuron diseases associated with hyperhomocysteinemia,” Frontiers in Cellular Neuroscience, vol. 9, article 391, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Liu, Y. Yang, D. Peng, L. Chen, and J. Luo, “Hyperhomocysteinemia as a metabolic disorder parameter is independently associated with the severity of coronary heart disease,” Saudi Medical Journal, vol. 36, no. 7, pp. 839–846, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Chan, S. H. Chui, D. Y. L. Wong, W. Y. Ha, C. L. Chan, and R. N. S. Wong, “Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction,” Life Sciences, vol. 75, no. 26, pp. 3157–3171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. D. P. Sieveking, K.-S. Woo, K. P. Fung, P. Lundman, S. Nakhla, and D. S. Celermajer, “Chinese herbs Danshen and Gegen modulate key early atherogenic events in vitro,” International Journal of Cardiology, vol. 105, no. 1, pp. 40–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Li, X. Cheng, J. Gu et al., “The effects of Gegen-Danshen prescription on the lipid metabolism in hyperlipidemia rats,” Journal of Southwest University for Nationalities: Natural Science Edition, vol. 36, no. 6, pp. 926–924, 2012. View at Google Scholar
  54. Z. Liu, S. Xu, X. Huang et al., “Cryptotanshinone, an orally bioactive herbal compound from Danshen, attenuates atherosclerosis in apolipoprotein E-deficient mice: role of lectin-like oxidized LDL receptor-1 (LOX-1),” British Journal of Pharmacology, vol. 172, no. 23, pp. 5661–5675, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. W. Zhao, C. Wu, and X. Chen, “Cryptotanshinone inhibits oxidized LDL-induced adhesion molecule expression via ROS dependent NF-κB pathways,” Cell Adhesion & Migration, 2015. View at Publisher · View at Google Scholar
  56. W. Jiang, Y. Zhao, B. Zhao, Q. Wan, and W. Xin, “Studies on the scavenging effect of Tanshinone on lipid free radical of cardiac sarcoplasmic reticulum during peroxidation,” Shengwu Wuli Xuebao, vol. 10, no. 4, pp. 685–689, 1993. View at Google Scholar
  57. S. Xu, Z. Liu, Y. Huang et al., “Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation,” Translational Research, vol. 160, no. 2, pp. 114–124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. Z.-P. Zhang, T.-T. You, L.-Y. Zou, T. Wu, Y. Wu, and L. Cui, “Effect of Danshen root compound on blood lipid and bone biomechanics in mice with hyperlipemia-induced osteoporosis,” Nan Fang Yi Ke Da Xue Xue Bao, vol. 28, no. 9, pp. 1550–1553, 2008. View at Google Scholar · View at Scopus
  59. O. Fadel, K. El Kirat, and S. Morandat, “The natural antioxidant rosmarinic acid spontaneously penetrates membranes to inhibit lipid peroxidation in situ,” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1808, no. 12, pp. 2973–2980, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. E. D. Michos and P. L. Lutsey, “25-hydroxyvitamin D levels and coronary heart disease risk reclassification in hypertension—is it worth the ‘hype’?” Atherosclerosis, vol. 245, pp. 237–239, 2016. View at Publisher · View at Google Scholar
  61. A. A. Nargesi, B. Heidari, S. Esteghamati et al., “Contribution of vitamin D deficiency to the risk of coronary heart disease in subjects with essential hypertension,” Atherosclerosis, vol. 244, pp. 165–171, 2016. View at Publisher · View at Google Scholar
  62. J. Liu, Y. Zou, Y. Tang et al., “Circulating cell-free mitochondrial deoxyribonucleic acid is increased in coronary heart disease patients with diabetes mellitus,” Journal of Diabetes Investigation, vol. 7, no. 1, pp. 109–114, 2016. View at Publisher · View at Google Scholar · View at Scopus
  63. R. N. Das, “Relationship between diabetes mellitus and coronary heart disease,” Current Diabetes Reviews, vol. 12, no. 999, pp. 1–12, 2016. View at Publisher · View at Google Scholar
  64. H. J. Dong, C. Huang, D. M. Luo et al., “Concomitant coronary and renal revascularization improves left ventricular hypertrophy more than coronary stenting alone in patients with ischemic heart and renal disease,” Journal of Zhejiang University SCIENCE B, vol. 17, no. 1, pp. 67–75, 2016. View at Publisher · View at Google Scholar
  65. N. Katakami, H. Kaneto, T.-A. Matsuoka et al., “Accumulation of oxidative stress-related gene polymorphisms and the risk of coronary heart disease events in patients with type 2 diabetes—an 8-year prospective study,” Atherosclerosis, vol. 235, no. 2, pp. 408–414, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. I. V. Gorudko, V. A. Kostevich, A. V. Sokolov et al., “Functional activity of neutrophils in diabetes mellitus and coronary heart disease: role of myeloperoxidase in the development of oxidative stress,” Bulletin of Experimental Biology and Medicine, vol. 154, no. 1, pp. 23–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. V. M. Provotorov, A. V. Budnevskii, G. G. Semenkova, and E. S. Shishkina, “Proinflammatory cytokines in combination of coronary heart disease and chronic obstructive pulmonary disease,” Klinicheskaia Meditsina, vol. 93, no. 2, pp. 5–9, 2015. View at Google Scholar
  68. G. L. Oktar, M. Kirisci, A. D. Dursun et al., “Antioxidative effects of adrenomedullin and vascular endothelial growth factor on lung injury induced by skeletal muscle ischemia-reperfusion,” Bratislava Medical Journal, vol. 114, no. 11, pp. 625–628, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. S. T. Ma, G. L. Dai, X. G. Cheng et al., “Synergistic action of Compound Danshen Dripping Pill (CDDP) on Clopidogrel Bisulfate (CPG) counteracting platelet aggregation,” Zhong Yao Cai, vol. 37, no. 10, pp. 1820–1825, 2014. View at Google Scholar
  70. Z. S. Huang, C. L. Zeng, L. J. Zhu, L. Jiang, N. Li, and H. Hu, “Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of phosphoinositide 3-kinase,” Journal of Thrombosis and Haemostasis, vol. 8, no. 6, pp. 1383–1393, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Y. K. Chan, “Interaction between warfarin and danshen (Salvia miltiorrhiza),” Annals of Pharmacotherapy, vol. 35, no. 4, pp. 501–504, 2001. View at Publisher · View at Google Scholar · View at Scopus